Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Essen Biotech
Washington University School of Medicine
Nantes University Hospital
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Medical College of Wisconsin
Dana-Farber Cancer Institute
ARCE Therapeutics, Inc.
Kura Oncology, Inc.
medac GmbH
Children's Hospital Medical Center, Cincinnati
City of Hope Medical Center
Fred Hutchinson Cancer Center
Baylor College of Medicine
Thomas Jefferson University
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
CERo Therapeutics Holdings, Inc.
City of Hope Medical Center
University of Illinois at Chicago
Case Comprehensive Cancer Center
AvenCell Therapeutics, Inc.
Sunshine Lake Pharma Co., Ltd.
Shanghai Jiao Tong University School of Medicine
Melbourne Health
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University of Birmingham
Celyad Oncology SA